Literature DB >> 18187257

Expression of prolyl-hydroxylases PHD-1, 2 and 3 and of the asparagine hydroxylase FIH in non-small cell lung cancer relates to an activated HIF pathway.

Alexandra Giatromanolaki1, Michael I Koukourakis, Francesco Pezzella, Helen Turley, Efthimios Sivridis, Demosthenes Bouros, George Bougioukas, Adrian L Harris, Kevin C Gatter.   

Abstract

The oxygen sensitive prolyl-hydroxylase domain enzymes (PHDs) and the asparagines hydroxylase (FIH, factor inhibiting HIF) regulate the transcriptional activity of HIFs. We assessed the expression of these enzymes in a series of 73 non-small cell lung carcinomas (NSCLC). A direct association of PHDs with FIH and of the PHDs/FIH with HIFs expression was noted. Thirty three of 73 cases had high HIF/PHD expression, predicting intense HIF activity; 19/73 cases had low HIF and high PHD expression mimicking the normal bronchial pattern; and 18/73 cases had low HIF/PHD (inactive HIF pathway). High lactate dehydrogenase LDH5 expression was noted in cases with high HIF/PHD phenotype. The value of such a classification in defining different metabolic phenotypes of NSCLC deserves further evaluation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18187257     DOI: 10.1016/j.canlet.2007.11.041

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  10 in total

1.  MicroRNA-31 contributes to colorectal cancer development by targeting factor inhibiting HIF-1α (FIH-1).

Authors:  Tao Chen; Li-Qing Yao; Qiang Shi; Zhong Ren; Le-Chi Ye; Jian-Min Xu; Ping-Hong Zhou; Yun-Shi Zhong
Journal:  Cancer Biol Ther       Date:  2014-02-12       Impact factor: 4.742

2.  The expression of prolyl hydroxylase domain enzymes are up-regulated and negatively correlated with Bcl-2 in non-small cell lung cancer.

Authors:  Sufeng Chen; Jie Zhang; Xuebing Li; Xiaoyang Luo; Jing Fang; Haiquan Chen
Journal:  Mol Cell Biochem       Date:  2011-07-12       Impact factor: 3.396

3.  Factor inhibiting HIF1α (FIH-1) functions as a tumor suppressor in human colorectal cancer by repressing HIF1α pathway.

Authors:  Tao Chen; Zhong Ren; Le-Chi Ye; Ping-Hong Zhou; Jian-Min Xu; Qiang Shi; Li-Qing Yao; Yun-Shi Zhong
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

Review 4.  The multifaceted role of EGLN family prolyl hydroxylases in cancer: going beyond HIF regulation.

Authors:  Silvia Strocchi; Francesca Reggiani; Giulia Gobbi; Alessia Ciarrocchi; Valentina Sancisi
Journal:  Oncogene       Date:  2022-06-15       Impact factor: 8.756

5.  Overexpression of the HIF hydroxylases PHD1, PHD2, PHD3 and FIH are individually and collectively unfavorable prognosticators for NSCLC survival.

Authors:  Sigve Andersen; Tom Donnem; Helge Stenvold; Samer Al-Saad; Khalid Al-Shibli; Lill-Tove Busund; Roy M Bremnes
Journal:  PLoS One       Date:  2011-08-22       Impact factor: 3.240

6.  A regulatory feedback loop between HIF-1α and PIM2 in HepG2 cells.

Authors:  Zhenhai Yu; Xiaoping Zhao; Yingying Ge; Teng Zhang; Liangqian Huang; Xiang Zhou; Lei Xie; Jianjun Liu; Gang Huang
Journal:  PLoS One       Date:  2014-02-05       Impact factor: 3.240

7.  Prolyl hydroxylase domain protein 3 and asparaginyl hydroxylase factor inhibiting HIF-1 levels are predictive of tumoral behavior and prognosis in hepatocellular carcinoma.

Authors:  Mingyang Ma; Shuyao Hua; Gang Li; Sumei Wang; Xue Cheng; Songqing He; Ping Wu; Xiaoping Chen
Journal:  Oncotarget       Date:  2017-02-21

8.  Prolyl hydroxylase 3 involvement in lung cancer progression under hypoxic conditions: association with hypoxia-inducible factor-1α and pyruvate kinase M2.

Authors:  Xiao Chu; Ming Xiang; Liang Feng; Hui Liu; Chao Zhou
Journal:  J Thorac Dis       Date:  2019-09       Impact factor: 2.895

9.  Gene Expression Levels of the Prolyl Hydroxylase Domain Proteins PHD1 and PHD2 but Not PHD3 Are Decreased in Primary Tumours and Correlate with Poor Prognosis of Patients with Surgically Resected Non-Small-Cell Lung Cancer.

Authors:  Ana Koren; Matija Rijavec; Tomaž Krumpestar; Izidor Kern; Aleksander Sadikov; Tanja Čufer; Peter Korošec
Journal:  Cancers (Basel)       Date:  2021-05-12       Impact factor: 6.639

Review 10.  [Advances of hypoxia and lung cancer].

Authors:  Xuebing Li; Jiacong You; Qinghua Zhou
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2013-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.